Explore 3 Stock Ideas & Industry Insights Download Free Report

Neptune Wellness Solutions Inc

Company price
None USD 0.00(0%)
Last update at 2024-04-09T03:58:13.103690Z
Market Cap
2.88M

Momentum Score

…

Neptune Wellness Solutions Inc. operates as a consumer packaged goods company in Canada, the United States, and internationally. It's product portfolio includes omega-3 fish oils and other nutritional products, as well as softgel solutions under the Biodroga brand; and provides MaxSimil, an omega-3 fatty acid delivery technology that uses enzymes to predigest omega-3 fatty acids. The company offers vegan multi-omega gummies and soft gels under the Forest Remedies brand; and organic baby food products under the Sprout brands. It offers its products through distributors, retail outlets, and grocery stores, as well as online on forestremedies.com and sproutorganics.com, and e-commerce sites. Neptune Wellness Solutions Inc. was incorporated in 1998 and is headquartered in Laval, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.36
Low
41.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
5.15%
Revenue TTM
43.72M
Revenue Per Share
95.08
Gross Profit TTM
-8.46M
Debt / Equity
-0.30
ROE
-818.48%
Net Debt
22.61M
ROCE
488.65%
Diluted EPS TTM
-44.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -120.02M -105.55M -160.55M -56.26M -23.02M
Minority interest 28.34M 9.45M 28.08M 28.08M 28.08M
Net income -81.71M -93.73M -154.80M -60.86M -23.19M
Selling general administrative 46.42M 60.54M 89.34M 64.66M 15.29M
Selling and marketing expenses - - -19.47M - -
Gross profit -3.34M -10.58M -35.58M -1.84M 7.61M
Reconciled depreciation 2.73M 6.08M 25.68M 8.38M 3.06M
Ebit -66.74M -87.49M -119.61M -66.87M -14.88M
Ebitda -63.05M -79.89M -95.65M -58.94M -11.84M
Depreciation and amortization 3.69M 7.60M 23.96M 7.93M 3.05M
Non operating income net other - - - - 0.00M
Operating income -66.74M -87.49M -119.61M -66.87M -14.88M
Other operating expenses -37.22M -20.71M -42.71M -22.57M 13.59M
Interest expense -5.00M -2.67M -2.20M -0.43M 0.22M
Tax provision 0.00M 0.00M -4.60M 4.60M 0.17M
Interest income 0.00M 0.01M 0.05M 0.15M 0.25M
Net interest income -2.32M -2.14M -0.24M -0.43M -0.21M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense -38.31M -11.82M 4.37M 4.60M 0.17M
Total revenue 71.11M 61.01M 44.49M 29.58M 24.44M
Total operating expenses -111.67M -92.30M -122.78M -53.99M -30.42M
Cost of revenue 74.45M 71.58M 80.07M 31.42M 16.83M
Total other income expense net -53.28M -18.06M -40.94M 10.61M -8.14M
Discontinued operations - - - - 0.00M
Net income from continuing ops -88.80M -84.42M -168.59M -60.86M -23.19M
Net income applicable to common shares - -74.97M -167.15M -60.86M -23.19M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 41.80M 131.22M 234.96M 168.78M 90.22M
Intangible assets 2.17M 27.07M 32.62M 25.52M 7.65M
Other current assets 15655598.00M 6.88M 6.90M 5.48M 0.82M
Total liab 79.05M 55.16M 62.09M 17.22M 19.98M
Total stockholder equity -83.38M -7.66M 73.41M 50.34M 28.41M
Deferred long term liab - - - - 0.00M
Other current liab -284984.16M 23.64M 26.26M 9.49M 16.97M
Common stock 435.12M 396.38M 385.36M 213.88M 131.08M
Capital stock 321.95M 317.05M 300.76M 150.81M 98.18M
Retained earnings -518.50M -404.04M -311.96M -163.53M -102.67M
Other liab - 0.09M 12.14M 6.79M 1.26M
Good will 3.28M 27.72M 31.99M 42.33M 6.75M
Other assets 0.00M 0.00M 7.06M 0.18M 4.15M
Cash 2.69M 10.91M 75.20M 16.58M 9.82M
Total current liabilities 55.46M 37.90M 43.75M 17.22M 19.98M
Current deferred revenue 285004.00M 0.29M 1.98M 0.01M 0.02M
Net debt 22.61M 3.44M -60.84M -13.21M -9.82M
Short term debt 7.88M 0.64M 0.23M 2.56M 2.60M
Short long term debt 7.54M - - 3.18M 3.47M
Short long term debt total 25.31M 14.35M 14.36M 3.37M 2.60M
Other stockholder equity 14.54M 7.66M -73.41M -50.34M -28.41M
Property plant equipment - 23.74M 50.45M 61.41M 47.02M
Total current assets 31.83M 46.74M 112.52M 38.80M 24.64M
Long term investments - 0.00M 7.24M 0.53M 4.00M
Net tangible assets - 4.29M 81.52M 75.78M 54.58M
Short term investments 0.02M 0.02M 0.02M 0.04M 0.05M
Net receivables 7.51M 7.60M 8.63M 7.61M 4.35M
Long term debt 15.41M 11.65M 14.21M - 0.00M
Inventory 17.58M 21.33M 21.76M 9.09M 5.04M
Accounts payable 27.74M 13.34M 15.28M 5.16M 3.00M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income -14.54M -7.81M 0.95M 3.89M 0.57M
Additional paid in capital - - - - 0.00M
Common stock total equity - - 379.64M 213.88M 131.08M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - 0.00M
Treasury stock - - - - 0.00M
Accumulated amortization - - - - 0.00M
Non currrent assets other -9.97M -84.47M -115.38M -129.80M -61.43M
Deferred long term asset charges - - - - 0.00M
Non current assets total 9.97M 84.47M 115.38M 129.80M 61.43M
Capital lease obligations 2.36M 2.71M 3.92M 1.59M 0.00M
Long term debt total - - - 1.14M 0.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments 2.36M 0.04M -13.17M -24.56M -6.49M
Change to liabilities - 1.09M 16.39M 5.18M 0.70M
Total cashflows from investing activities - -2.33M -13.17M -24.56M -6.49M
Net borrowings - - -3.70M -0.82M -1.23M
Total cash from financing activities 26.07M 7.44M 144.54M 62.51M 0.19M
Change to operating activities - -3.16M -18.29M -4.12M 7.24M
Net income -81.71M -93.73M -154.80M -60.86M -23.19M
Change in cash -8.22M -64.29M 58.63M 6.76M -14.47M
Begin period cash flow 10.91M 75.20M 16.58M 9.82M 24.29M
End period cash flow 2.69M 10.91M 75.20M 16.58M 9.82M
Total cash from operating activities -38.61M -67.94M -71.19M -31.43M -8.15M
Issuance of capital stock 11.00M 8.00M 120.45M 43.04M -
Depreciation 3.69M 7.60M 23.96M 8.31M 3.05M
Other cashflows from investing activities - - 0.06M 0.16M 2.60M
Dividends paid - - -116.62M -38.69M 0.00M
Change to inventory -2.73M -3.34M -22.16M -4.74M 0.22M
Change to account receivables -2.18M -0.20M -10.71M -5.10M -0.17M
Sale purchase of stock -0.78M -1.76M -0.90M -0.96M 1.70M
Other cashflows from financing activities 15.85M 1.21M 144.54M 62.51M 0.19M
Change to netincome - 27.16M 87.65M 29.73M 3.98M
Capital expenditures 1.26M 2.42M 8.32M 13.79M 6.74M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital -4.91M -3.55M -32.87M -9.84M 0.06M
Stock based compensation 4.95M 10.00M 14.86M 35.19M 3.71M
Other non cash items 39.42M 18.18M 81.31M -7.47M 11.99M
Free cash flow -39.87M -70.37M -79.51M -45.22M -14.89M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
-0.22
0.66%
33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-2.76
1.62%
167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.17
0.80%
21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Neptune Wellness Solutions Inc

Neptune Wellness Solutions Inc. operates as a consumer packaged goods company in Canada, the United States, and internationally. It's product portfolio includes omega-3 fish oils and other nutritional products, as well as softgel solutions under the Biodroga brand; and provides MaxSimil, an omega-3 fatty acid delivery technology that uses enzymes to predigest omega-3 fatty acids. The company offers vegan multi-omega gummies and soft gels under the Forest Remedies brand; and organic baby food products under the Sprout brands. It offers its products through distributors, retail outlets, and grocery stores, as well as online on forestremedies.com and sproutorganics.com, and e-commerce sites. Neptune Wellness Solutions Inc. was incorporated in 1998 and is headquartered in Laval, Canada.

545 Promenade du Centropolis, Laval, QC, Canada, H7T 0A3

450 687 2262

50

Name Title Year Born
Mr. Michael Cammarata Pres, CEO & Director 1986
Mr. John S. Wirt Chief Legal Officer, Exec. VP of Legal & Bus. Affairs and Gen. Counsel 1963
Mr. Raymond P. Silcock Exec. VP & CFO 1951
Mr. Morry Brown VP of Investor Relations NA
Mr. Gary S. Kaminsky Sr. VP of Compliance & Legal Affairs NA
Ms. Jessica Adkins Sr. VP of Corp. Communications NA
Mr. Roger Corriveau Vice-Pres of Bus. Devel. 1948
Mr. Marc Vaugeois VP of Sales NA
Ms. Sabrina Di Blasio Director of Marketing & Communications NA
Ms. Paola Patti Director HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…